NASDAQ: IKTInhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?
Insider buying vs selling
Have Inhibikase Therapeutics Inc insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.
Be the first to know when IKT insiders and whales buy or sell their stock.
IKT Shareholders
What type of owners hold Inhibikase Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Sands Capital Alternatives LLC | 14.69% | 10,950,000 | $16.86M | Institution |
| Sands Capital Life Sciences Pulse Fund II LP | 14.69% | 10,950,000 | $16.86M | Insider |
| Soleus Capital Management LP | 8.49% | 6,325,000 | $9.74M | Institution |
| Fairmount Funds Management LLC | 8.22% | 6,125,000 | $9.43M | Institution |
| Perceptive Advisors LLC | 7.29% | 5,432,293 | $8.37M | Institution |
| Commodore Capital LP | 7.24% | 5,397,488 | $8.31M | Institution |
| Milton H. Werner | 7.19% | 5,359,022 | $8.25M | Insider |
| Adar1 Capital Management LLC | 6.87% | 5,122,105 | $7.89M | Institution |
| Vanguard Group Inc | 4.33% | 3,224,370 | $4.97M | Institution |
| Blackrock Inc | 3.66% | 2,728,168 | $4.20M | Institution |
IKT vs Biotech Stocks
Inhibikase Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.